Separation Or Purification Patents (Class 530/412)
  • Patent number: 10156565
    Abstract: The present invention relates to a peptide, a magnetic peptide and a method for detecting coeliac disease. It also relates to a deaminated peptide used to prepare said magnetic peptide and to the use of both to detect coeliac disease. Said deaminated peptide comprises a histidine tag and is bonded to a particulated magnetic complex. It also relates to an immunosensor that comprises said magnetic peptide, to an appropriate method for detecting coeliac disease based on a magnetic immunoassay and to a kit that comprises said magnetic peptide.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: December 18, 2018
    Assignee: UNIVERSITAT AUTONOMA DE BARCELONA
    Inventors: María I. Pividori Gurgo, Silvina V. Kergaravat
  • Patent number: 10125199
    Abstract: A method for the production of particles by reacting functional groups on the surface of non-magnetic porous particles with functional groups on the surface of magnetic particles to form a covalent bond, to obtain particles supplemented with magnetic particles covalently bound to the outer part of said particles. Advantages include an increased binding capacity.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: November 13, 2018
    Assignee: Lab-on-a-bead AB
    Inventors: Sven Oscarsson, Kristofer Eriksson, Peter Svedlindh
  • Patent number: 10125189
    Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: November 13, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
  • Patent number: 10099156
    Abstract: A chromatographic purification method for the isolation of a desired product fraction from a mixture using 2 chromatographic columns, comprises, within one cycle to be carried out at least once, the following steps: a first batch step, wherein said columns are disconnected and a first column is loaded with feed and its outlet is directed to waste, and from a second column desired product is recovered and subsequently the second column is regenerated; a first interconnected step, wherein the outlet of the first column is connected to the inlet of the second column, the first column is loaded beyond its dynamic breakthrough capacity with feed, and the outlet of the second column is directed to waste, a second batch step analogous to the first batch step but with exchanged columns; and a second interconnected step, analogous to the first interconnected step but with exchanged columns.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: October 16, 2018
    Assignee: ChromaCon AG
    Inventors: Thomas Müller-Späth, Lars Aumann, Guido Strohlein, Michael Bavand, Nicole Ulmer
  • Patent number: 10071364
    Abstract: Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/or chelator are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation. Also provided are reduced bioburden chromatography columns including the reduced bioburden chromatography resin, compositions including a chromatography resin and at least one chelator and/or antioxidant agent, methods of performing reduced bioburden column chromatography using one of these reduced bioburden chromatography columns, and integrated, closed, and continuous processes for reduced bioburden manufacturing of a purified recombinant protein.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: September 11, 2018
    Assignee: Genzyme Corporation
    Inventors: Rahul Godawat, Veena Warikoo, Rohan Patil, Konstantin Konstantinov, Venkat Kishore Ryakala
  • Patent number: 9963516
    Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: May 8, 2018
    Assignee: Immunomedics, Inc.
    Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
  • Patent number: 9943825
    Abstract: Provided are graft copolymer particles enabling introduction of adsorptive functional groups adsorbing metals and others, a method for producing same, and an adsorbent using same. (1) Porous graft copolymer particles containing graft chains introduced into porous particles (particle surface having an average pore diameter of 0.01-50 ?m) including at least one resin selected from olefin resins, water-insoluble modified polyvinyl alcohol resins, amide resins, cellulosic resins, chitosan resins and (meth)acrylate resins. (2) A method for producing porous graft copolymer particles including (I) melt-kneading a polymer A and a polymer B other than the polymer A to obtain a compound material, (II) extracting and removing the polymer B from the compound material to obtain a porous material of the polymer A, (III) granulating the porous material, and (IV) introducing graft chains into the porous particles. (3) An adsorbent of porous graft copolymer particles.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: April 17, 2018
    Assignee: KURARAY CO., LTD.
    Inventors: Keisuke Morikawa, Yusuke Amano, Naoyuki Iwachido, Naoki Fujiwara, Takumi Takayama
  • Patent number: 9939439
    Abstract: The invention concerns a microfluidic system (1) comprising: at least one channel (2) for the flow of fluid having an inlet (4), an outlet (5) and a longitudinal axis (7) extending between the inlet (4) and the outlet (5), said channel (2) comprising a capture zone (3), and the cross section of the channel (2) orthogonal to the longitudinal axis (7) of the channel (2) increasing in size in the capture zone (3), from the inlet (4) towards the outlet (5) of the channel (2); and means (6) for applying a magnetic field having a decreasing intensity in the capture zone (3) of the channel (2), from the inlet (4) towards the outlet (5) of the channel. The invention also concerns a method for treating a sample that can be implemented with this system.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: April 10, 2018
    Inventors: Jean-Louis Viovy, Sanae Tabnaoui, Laurent Malaquin, Stéphanie Descroix
  • Patent number: 9738694
    Abstract: The present invention relates to a porcine alpha-S1-casein gene, a porcine alpha-S1-casein gene promoter, an expression comprising the same promoter, and a method for the production of a target protein using the same expression vector. The promoter of the present invention facilitates the mammary gland-specific expression of the target protein. Accordingly, an animal transformed with the promoter secretes the target protein in milk at high concentration, and thus can be advantageously used for the production of useful proteins.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: August 22, 2017
    Assignee: CHO-A PHARM. CO., LTD.
    Inventors: Myeong Goo Yeo, Sung-Jo Kang, Jong Deok Ahn
  • Patent number: 9645156
    Abstract: The present invention provides a method for determining glycosylation and terminal modifications of immunoglobulin during immunoglobulin purification process, which can simultaneously and rapidly determine glycosylation, N-terminal pyroglutamination and C-terminal de-lysination of immunoglobulin, including Step 1) separating immunoglobulin by using cation-exchange resin, and collecting different components in according to retention time; Step 2) denaturing the components of immunoglobulin obtained in step 1) with a denaturant, followed by reducing them with a reducing agent, to separate the light chain and heavy chain; Step 3) separating the light chain and heavy chain of immunoglobulin of step 2) by using reverse phase ultrahigh pressure liquid chromatography; Step 4) measuring the molecular weights of the light chain and heavy chain obtained in step 3) with mass spectrum; and Step 5) analyzing the chromatographic data obtained in step 3) and the mass spectrometric data obtained in step 4) to determine glyco
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: May 9, 2017
    Assignee: LIVZON MABPHARM INC.
    Inventors: Baoguo Zhu, Yucai Peng, Jiaming Yang
  • Patent number: 9630165
    Abstract: Provided herein are methods of reducing bioburden of (e.g., sterilizing) a chromatography resin that include exposing a container including a composition including a chromatography resin and at least one antioxidant agent and/or chelator to a dose of gamma-irradiation sufficient to reduce the bioburden of the container and the chromatography resin, where the at least one antioxidant agent and/or chelator are present in an amount sufficient to ameliorate the loss of binding capacity of the chromatography resin after/upon exposure to the dose of gamma-irradiation. Also provided are reduced bioburden chromatography columns including the reduced bioburden chromatography resin, compositions including a chromatography resin and at least one chelator and/or antioxidant agent, methods of performing reduced bioburden column chromatography using one of these reduced bioburden chromatography columns, and integrated, closed, and continuous processes for reduced bioburden manufacturing of a purified recombinant protein.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: April 25, 2017
    Assignee: Genzyme Corporation
    Inventors: Rahul Godawat, Veena Warikoo, Rohan Patil, Konstantin Konstantinov, Venkat Kishore Ryakala
  • Patent number: 9488659
    Abstract: The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
    Type: Grant
    Filed: April 11, 2013
    Date of Patent: November 8, 2016
    Assignee: B.R.A.H.M.S. GmbH
    Inventors: Joachim Struck, John G F Cleland
  • Patent number: 9486514
    Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: November 8, 2016
    Assignee: Wake Forest University Health Sciences
    Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
  • Patent number: 9416416
    Abstract: Disclosed are compositions for collecting, storing, and transporting populations of nucleic acids from biological specimens, and clinical, forensic, or environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. In particular embodiments, the invention provides a single, one-step, sample collection/transport/storage formulation containing a known quantity of a non-genomic, nucleic acid carrier molecule that serves as an internal reference control to monitor the fidelity of the collection/transportation medium, and measure the integrity of nucleic acids subsequently isolated and purified from the processed sample.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: August 16, 2016
    Assignee: Longhorn Vaccines and Diagnostics, LLC
    Inventors: Gerald W. Fischer, Luke T. Daum
  • Patent number: 9339531
    Abstract: A critical epitope of human cytochrome P4502E1 (CYP2E1) associated with the development of hepatic autoimmune disease, including methods and kits for diagnosis and prognosis using the critical epitope as a biomarker for hepatic autoimmune disease.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: May 17, 2016
    Assignee: The Johns Hopkins University
    Inventor: Dolores Benedicta Njoku
  • Patent number: 9315574
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: April 19, 2016
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Patent number: 9134311
    Abstract: This invention relates to an immunogenic molecule comprising a contiguous amino acid sequence of an invasion ligand of a strain of Plasmodium falciparum, the invasion ligand capable of binding to an erythrocyte receptor, the receptor function being resistant to trypsin and neuraminidase and chymotrypsin, wherein when administered to a subject the molecule is capable of inducing an immune response to the strain. The invention further relates to compositions and methods for the treatment of diseases such as malaria.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: September 15, 2015
    Assignee: Walter and Eliza Hall Institute of Medical Research
    Inventors: Alan Cowman, Lin Chen, Jacob Baum
  • Patent number: 9109015
    Abstract: The present invention is related to a method of isolating a biological macromolecule in a composition. Specifically, the present invention is directed to a method of isolating a biomacromolecule in a composition containing an impurity, the method comprising (a) lowering the pH of the composition, (b) adding a divalent cation to the composition, and (c) separating the biomacromolecule from the impurity.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: August 18, 2015
    Assignee: BIOGEN MA INC
    Inventors: Jonathan Romero, James Chrostowski, Philippe Georges De Vilmorin, Jennifer Yun Case
  • Patent number: 9073969
    Abstract: The invention relates to compounds which can be used for purifying peptides produced by solid phase peptide synthesis. In addition, the invention relates to methods for purifying peptides produced by solid phase peptide synthesis using the compounds according to the invention.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: July 7, 2015
    Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS
    Inventors: Vincent Aucagne, Agnes Delmas
  • Patent number: 9040672
    Abstract: Devices and methods are provided for reducing matrix effects in protein precipitated bioanalytical samples comprising: a support, and a sorbent associated with the support capable of binding matrix interfering agents present in the bioanalytical sample, wherein the device further comprises filtering means for removing precipitated protein particles. The filtering means is a size exclusion filter or a polymeric or inorganic monolith having a maximum pore size less than or equal to the diameter of the particles to be removed from the sample, and can be integral with the sorbent or associated with the sorbent. The sorbent is characterized by sufficient selectivity between the matrix interfering agents and analytes of interest to provide retention of the matrix interfering agents while providing elution of the analytes of interest (e.g., a reversed phase or a polar modified reversed phase).
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 26, 2015
    Assignee: Agilent Technologies, Inc.
    Inventor: David C. Jones
  • Patent number: 9035031
    Abstract: The present invention relates to isolation of whey proteins and the preparation of a whey product and a whey isolate. In particular the present invention relates to the isolation of a ?-lactoglobulin product and the isolation of an ?-enriched whey protein isolate from whey obtained from an animal. The ?-enriched whey protein isolate provided by the present invention is besides from being low in ?-lactoglobulin also high in ?-lactalbumin and immunoglobulin G.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: May 19, 2015
    Assignee: UPFRONT CHROMATOGRAPHY A/S
    Inventors: Marie Bendix Hansen, Allan Otto Fog Lihme, Malene Fog Lihme
  • Patent number: 9034798
    Abstract: Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.
    Type: Grant
    Filed: February 26, 2010
    Date of Patent: May 19, 2015
    Assignee: CAPROTEC BIOANALYTICS GMBH
    Inventors: Hubert Köster, Daniel Paul Little, Suhaib Mahmood Siddiqi, Matthew Peter Grealish, Subramanian Marappan, Chester Frederick Hassman, III, Ping Yip
  • Patent number: 9029102
    Abstract: A process is provided for the preparation of a highly pure albumin solution the process comprising subjecting albumin (preferably expressed and secreted by transformed yeast) to a series of chromatographic steps. Preferably, the process comprises the steps of positive mode cation exchange chromatography, positive mode anion exchange chromatography, positive mode affinity chromatography, negative mode affinity chromatography (preferably using immobilized aminophenylboronic acid), negative mode cation exchange chromatography, and negative or positive mode anion exchange chromatography. A process for reducing the level of nickel in an albumin solution is also disclosed, as is a recombinant albumin coding sequence comprising two or more in-frame translation stop codons.
    Type: Grant
    Filed: July 1, 2011
    Date of Patent: May 12, 2015
    Assignee: Novozymes Biopharma DK A/S
    Inventors: Hendrik Van Urk, Philip Harvey Morton, Andrew John Cartwright, Jason Cameron, David James Ballance, Michael Gaston Joseph Grandgeorge, Stephen Berezenko, John Rodney Woodrow, Jean-Luc Bernard Veron
  • Patent number: 9024000
    Abstract: The present invention relates to a method to improve the sorbent efficiency of protein A chromatography using switching column with continuous feeding. In the chromatography method of the present invention, the increased usage efficiency of the absorbent (resin), the decreased processing time, the decreased operation cycle of column compared to that of single batch-type column, and the reduced amount of used resin are achieved and thus, the target protein can be purified at a high efficiency and a low cost.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: May 5, 2015
    Assignee: Celltrion, Inc.
    Inventors: Su Hi Jeon, Jin-Il Kim
  • Patent number: 9023994
    Abstract: The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.
    Type: Grant
    Filed: May 14, 2012
    Date of Patent: May 5, 2015
    Assignee: Omrix Biopharmaceuticals, Ltd.
    Inventors: Roni Mintz, Oleg Belyaev, Israel Nur, Liliana Bar, Roberto Meidler
  • Patent number: 9012212
    Abstract: A method and system is provided for yielding biopharmaceutical products involving a chromatographic separation process. The method comprises: providing a plurality of membrane adsorber cartridges; providing a plurality of valves, communicatively coupled to said plurality of membrane adsorber cartridges; and switching the valves, so as to interconnect said membrane adsorber cartridges to operate in a countercurrent flow mode. The system comprises multiple membrane adsorber cartridges that are interconnected and configured to operate in a countercurrent flow mode. Furthermore, the configuration comprises a valve assembly that allows the cartridges to be subjected to different steps in the process by automatic switching of the valves. In this way, cartridges are recycled many times during the purification of a batch.
    Type: Grant
    Filed: April 17, 2007
    Date of Patent: April 21, 2015
    Assignee: Xendo Holding B.V.
    Inventors: Marc Antonius Theodorus Bisschops, Jozef Anton Mari Pennings, Jacob Arthur Tijsterman
  • Patent number: 9006401
    Abstract: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to impaired physical vigor or aptitude, and aging and/or age-related conditions (arthritis, mobility deficits, loss of appetite, etc.). Additional aspects provide methods for building muscle mass, for reducing exercise recovery period, or for sustaining exercise intensity. Particular aspects relate to preparation of Houttuynia cordata extracts and the use of those extracts as an anti-emetic and/or anti-nausea treatment for a subject in need thereof.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: April 14, 2015
    Assignee: CMI Research Management, LLC
    Inventor: Richard N. Ushijima
  • Patent number: 8993350
    Abstract: The present invention relates generally to a novel method using HPLC and fluorescence detection of free PEG-mal in PEGylated proteins and PEG-mal raw materials by adding a fluorescent label to the free PEG-mal.
    Type: Grant
    Filed: January 29, 2010
    Date of Patent: March 31, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mei Lin, Anulfo Valdez
  • Patent number: 8993734
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: March 31, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nürnberger, Wolfgang Teschner, Harald Arno Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Patent number: 8981067
    Abstract: Compositions relating to a combination of two types of separation matrix; and to variant host cells which contain at least one essential host protein that is fused to an affinity binding tag or has been mutated to replace at least two of a plurality of histidines or basic amino acids are provided. Methods are also provided that relate to isolating a recombinant protein from a lysate.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: March 17, 2015
    Assignee: New England Biolabs, Inc.
    Inventors: James C. Samuelson, Carine Robichon-Iyer, Jianying Luo
  • Patent number: 8975383
    Abstract: The present invention provides a method for producing a protein which has a restored native higher-order structure by bringing a protein which has lost its native higher-order structure into contact at pH 6.5 to 9.0 with a 1 to 3% aqueous solution of a specific surfactant, such as lauroylglutamic acid to obtain a solubilized solution of the protein; and then adding the solubilized solution to a buffer with pH 6.5 to 9.0 containing arginine or an arginine derivative at a concentration of 0.1 to 1.2 M to lower the concentration of the specific surfactant, such as lauroylglutamic acid, in the obtained mixture solution down to 0.02 to 0.275%. According to the present invention, it is possible to easily restore the native higher-order structure of a protein while smoothly removing the surfactant from the protein.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: March 10, 2015
    Assignee: Ajinomoto Co., Inc.
    Inventors: Ryosuke Yumioka, Daisuke Ejima
  • Patent number: 8969036
    Abstract: The present invention relates to the manufacture of recombinant antibodies of therapeutic quality. In particular, the invention relates to methods for increasing the yield of functional antibody from large scale fermentations whereby a cultured host cell sample is subjected to a non-lysing treatment.
    Type: Grant
    Filed: November 16, 2005
    Date of Patent: March 3, 2015
    Assignee: UCB Pharma S.A.
    Inventors: Mukesh Sehdev, Mariangela Spitali
  • Patent number: 8969533
    Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: March 3, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
  • Patent number: 8969532
    Abstract: The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: March 3, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Shawn DeFrees, Kyle Kinealy
  • Patent number: 8962813
    Abstract: A process for manufacturing of a composition containing a purified factor for supporting wound healing selected from the group consisting of Hepatocyte Growth Factor (HGF) platelet derived growth factor (PDGF), Epidermal growth factor (EGF), transforming growth factor alfa (TGF-?), Transforming growth factor beta (TGF-?), insulin like growth factor (IGF-I) and Fibroblast growth factor (FGF) from sources, such as blood, containing the factor for supporting wound healing, wherein the manufacturing process comprises purification steps which are performed in the presence of antithrombin III (AT-III).
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: February 24, 2015
    Assignee: Octapharma AG
    Inventors: Andrea Neisser-Svae, Stefan Winge, Anna Mjärdestam
  • Patent number: 8962812
    Abstract: A method is provided for extraction of chemical compounds from an organism having a cell wall that includes adding nanomaterials, which may be metallic nanofibers such as silver nanofibers, to the organism.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: February 24, 2015
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Maria Teresa Gutierrez-Wing, Kelly Ann Rusch
  • Patent number: 8962814
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: February 24, 2015
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Patent number: 8957190
    Abstract: The present invention relates to a solid support having a heat-resistant biotin-binding protein attached thereto. The present invention also relates to the use of the solid support of the present invention having a heat-resistant biotin-binding protein attached thereto. The present invention further relates to technical fields such as purification, concentration, detection and/or capture of a biotin-linked substance by means of a heat-resistant biotin-binding protein. Such a biotin-binding protein used in the solid support of the present invention is heat-resistant and is therefore useful for use in assay systems involving exposure to a temperature of 70° C. or more.
    Type: Grant
    Filed: July 11, 2013
    Date of Patent: February 17, 2015
    Assignee: Japan Tobacco Inc.
    Inventors: Yoshimitsu Takakura, Satoru Usami, Masako Ichikawa
  • Patent number: 8951807
    Abstract: The present invention discloses methods of neutralizing apatite surfaces, for example during chromatography and before protein elution.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: February 10, 2015
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Larry J. Cummings, Mark A. Snyder
  • Patent number: 8952137
    Abstract: A method is provided for producing soluble thrombomodulin substantially not containing a denatured product of the soluble thrombomodulin that is generated under acidic conditions, which comprises: subjecting the soluble thrombomodulin-containing material to an anion exchanger or hydroxyapatite; and carrying out linear gradient elution, stepwise gradient elution, or gradient elution in which linear gradient elution is combined with stepwise gradient elution under separation conditions in which the denatured product of the soluble thrombomodulin can be separated, wherein the gradient is a salt concentration gradient, so as to obtain an elution fraction containing soluble thrombomodulin that does not substantially contain the denatured product of the soluble thrombomodulin, either (a) after the position of a fraction has previously been confirmed, or (b) while confirming the elution fraction.
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: February 10, 2015
    Assignee: Asahi Kasei Pharma Corporation
    Inventor: Susumu Ohigashi
  • Patent number: 8946395
    Abstract: The present invention is directed to methods for purifying a protein of interest, e.g., an antibody, from a sample comprising the protein of interest and at least one impurity, e.g., an aggregate, by employing a hydrophobic interaction chromatography (HIC) method that allows for binding of both the protein of interest and the at least one impurity under strong binding conditions. The present invention is based, at least in part, on the finding that both flow through and bind-elute techniques can be combined to achieve greater purification and recovery of a protein of interest, e.g., an antibody, under isocratic wash conditions and strong binding conditions.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: February 3, 2015
    Assignee: AbbVie Inc.
    Inventors: Matthew Omon Herigstad, Linda E. Rich, Stephen Ming-teh Lu, Natarajan Ramasubramanyan
  • Patent number: 8945872
    Abstract: Expression vector systems are provided for increased production of a recombinant GDF-5 (rhGDF-5) protein. Also provided are transformed host cells that were engineered to produce and express high levels of rhGDF-5 protein. Methods for production and high expression of rhGDF-5 protein are disclosed herein. The methods of enhancing production and protein expression of rhGDF-5 protein as disclosed are cost-effective, time-saving and are of manufacturing quality.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: February 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David S. Scher, Roger E. Harrington
  • Publication number: 20150030681
    Abstract: The present invention relates to a novel protocol for making a hydrogel, which shows increased stability compared to hydrogels of the art, and can be reliably reproduced. The hydrogels produced by the methods of the present invention are preferably three dimensional, and particularly suitable for the culture of stem cells.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 29, 2015
    Applicant: The University of Manchester
    Inventors: Catherine Louise Ruby Merry, Alberto Saiani, Kate Alexandra Meade, Emma Tranquility Lowe, Aline Fiona Saiani, Jean-Baptiste Guilbaud
  • Publication number: 20150031145
    Abstract: Compositions, methods, articles of manufacture, and kits are provided for storage and delivery of proteins.
    Type: Application
    Filed: July 24, 2014
    Publication date: January 29, 2015
    Inventors: Clayton T. McKee, William Strong
  • Patent number: 8940875
    Abstract: The invention includes a process for extracting a target protein from Escherichia coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 27, 2015
    Assignee: Genentech, Inc.
    Inventor: Richard L. Gehant
  • Patent number: 8940877
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Grant
    Filed: October 16, 2012
    Date of Patent: January 27, 2015
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Arno Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Patent number: 8933205
    Abstract: The invention provides a process for preparing a cell-binding agent chemically coupled to a drug. The process comprises covalently attaching a linker to a cell-binding agent, a purification step, conjugating a drug to the cell-binding agent and a subsequent purification step.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: January 13, 2015
    Assignee: ImmunoGen, Inc.
    Inventors: Yong Dai, Yong Wang, Shengjin Jin, Deborah H. Meshulam, Godfrey W. Amphlett
  • Patent number: 8933204
    Abstract: The invention relates to a novel, industrial-scale process for the purification of gamma-immunoglobulins (IgG) starting from plasma or fractions thereof. The method involves two chromatographic steps, i.e. a cation exchange capture chromatography, and then a polishing anion exchange chromatography, ensuring a highly purified end product, which contains no aggregates, and high yields. The process also involves a virus inactivation step by means of a solvent/detergent treatment to inactivate the viruses with a lipid envelope, and a virus removal step by nanofiltering to ensure the removal of the non-enveloped viruses.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: January 13, 2015
    Assignee: Kedrion S.p.A.
    Inventors: Claudia Nardini, Andrea Morelli, Claudio Farina, Sabrina Esposito, Alessandra Lazzarotti, Arianna Petrucci
  • Patent number: 8927290
    Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: One Lambda, Inc.
    Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
  • Patent number: 8921530
    Abstract: The present invention relates to a process for the purification of a protease.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: December 30, 2014
    Assignee: Novo Nordisk Healthcare AG
    Inventor: Janus Krarup